VAUGHAN, Ontario / Apr 15, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2024 financial results on Wednesday, May 1, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call.
Conference Call Details
Date: | Wednesday, May 1, 2024 | |
Time: | 8 a.m. ET | |
Webcast: | ||
Participant Event Dial-in: | +1 (888) 506-0062 (North America) +1 (973) 528-0011 (International) | |
Participant Access Code: | 357966 | |
Replay Dial-in: | +1 (877) 481-4010 (North America) +1 (919) 882-2331 (International) | |
Replay Passcode: | 49631 (replay available until May 15, 2024) |
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.
© 2024 Bausch + Lomb.
| Last Trade: | US$14.53 |
| Daily Change: | 0.09 0.62 |
| Daily Volume: | 168,592 |
| Market Cap: | US$5.140B |
August 18, 2025 July 30, 2025 July 29, 2025 June 04, 2025 May 21, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
